Please note: The University of Texas Health Science Center at San Antonio will now be called "UT Health San Antonio."

Search Program Faculty/Research

Ralph A. DeFronzo, M.D.

5d4d79453d0fda4c2442f55557581d29

RESEARCH

Dr. Ralph DeFronzo's major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus and the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders known collectively as the Insulin Resistance Syndrome. Using the euglycemic insulin clamp technique in combination with radioisotope turnover methodology, limb catheterization, indirect calorimetry, and muscle biopsy, he has helped to define the biochemical and molecular disturbances responsible for insulin resistance in type 2 diabetes mellitus.

Selected Publications

Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS Endocr Pract 2016 Jun;22(6):753-762.

Tripathy D, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: Results from ACT NOW J Clin Endocrinol Metab 2016 May;101(5):2056-2062.

DeFronzo RA, MD, Chilton R, MD, Norton L, Geoffrey Clarke G, Ryder REJ, Abdul-Ghani M. Revitalization of pioglitazone: the optimal agent to be combined with an SGLT2 inhibitor Diabetes, Obesity, & Metabolism 2016 May: 18 (5):454-62.

699.DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY Diabetologia 2016 Jan;59:1645-1654.

700.Wilding JPH, Rajeev SP, DeFronzo RA. Positioning SGLT2 inhibitors/incretin based therapies in the treatment algorithm Diabetes Care 2016 Jan;39:S154-S164.

Abdul-Ghani M, DeFronzo RA, Jayyousi A. Pre-diabetes and risk of diabetes and associated complications ? impaired fasting glucose vs impaired glucose tolerance: does it matter? 2016 Jul 6 [Epub ahead of print] Curr Opin Clin Nutr Metabolic Care 2016 Jan;.

Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, DeFronzo RA, Norton L, Abdul-Ghani M. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care 2016 Nov; 39 (11)" 2036-2041. Epub 2016 Aug 25. 

Daniele G, Eldor R, Huerta C, Alatrach M, Adams J, DeFronzo RA, Duong T, Lancaster J, Zirie M, Jayyousi A, Abdul-Ghani M. Discordance between central (brain) and pancreatic action of exenatide in lean and obese subjects. Diabetes Care  2016 Oct: 39(10): 1804-10.

Buse J, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The primary glucose-lowering effect of metformin resides in the gut not the circulation. Results from short-term pharmacokinetic and 12-week dose ranging studies Diabetes Care 2016 Jan;39:198-205.

Merovci A, Abdul-Ghani M, Mari A, Solis-Herrera C, Xiong J, Daniele G, Tripathy D, DeFronzo RA. Effect of dapagliflozin with and without acipimox on insulin sensitivity and insulin secretion in T2DM individuals JCEM 2016 March:101 (3).1249-56.

Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EPMA-REG OUTCOME trial. (Accepted for Publication) Diabetes Care 2016 Jan;39:717-725.

Doiron B, Hu W, DeFronzo RA. Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type Adult Mice Curr Pharm Biotechnol 2016 Jan;17(4):376-388.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY Endocr Pract 2016 Jan;22(1):84-113.

Muscogiuri G, DeFronzo R, Gastaldelli A, Holst JJ. Gulcagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends Endocrinol Metab. 2017 Feb; 28 (2):88-103, doi; 10.1016/j.tem.2016.10.001. Epub 2016 Oct 27. 

Professor & Division Chief
Medicine/Diabetes

Education

M.D., Medicine, Harvard Medical School, 1969

M.S., Medicine, Boston College Graduate School of Biology, 1969

BMS, Medicine, Dartmouth Medical School

B.S., Biology/Biochemistry, Yale University, 1964

Contact

Email: DEFRONZO@UTHSCSA.EDU

Phone: (210) 567-6691

Research Profile
More Info...